We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Eli ...

Also, with the acquisition of Morphic Holding in 2024, Eli Lilly now has MORF-057, a small oral molecule inhibitor, that is being evaluated in phase 2 studies (ulcerative colitis and Crohn's disease).

Goldman Sachs upgraded Eli Lilly (LLY) to Buy from Neutral with a price target of $888, down from $892, after assuming coverage of the name.